• Watchlist/Portfolio

    Add to watchlist:

    Only registered members can add into watchlist !

    Register here !
Advertisement

Plethora Solutions (AIM: PLE) is a speciality pharmaceutical company dedicated to the development and marketing of products for the treatment and management of urological disorders. The diagnosis and treatment of urological conditions represents an expanding market with many poorly met medical needs that offer significant commercial potential for new pharmaceutical products and medical devices.

Website:
http://www.plethorasolutions.co.uk
Phone:
+44 (0)20 3077 5400
Address:
1st Floor, St Andrew?s House, 18-20 St Andrew Street, London, EC4A 3AG
Super Sector:
Pharmaceuticals & Biotechnology
Sector:
Pharmaceuticals & Biotechnology
Industry:
Pharmaceuticals
EPIC / Symbols:
LON:PLE
chart-size
*subject to change and depends on individual circumstances.

Plethora Solutions RNS Press Releases

rss
  • Page 1 of 26

Plethora Solutions Articles, News, and Media Files

rss
  • Page 1 of 5

Plethora Solutions Related Media

rss
  • Page 1 of 5
  • 12/06/2012

    Stocktube video - Plethora Solutions now focused on commercialisation of its premature ejaculation treatment

    Ronald Openshaw, CEO at Plethora Solutions (LON:PLE), tells Proactiveinvestors that the early submission of the dossier to the European Medicines Agency for the approval of the premature ejaculation treatment PSD502 is “huge news”. Ronald says that it’s likely to take 12-18 months for approval then it’s the launch. Ahead of that then management will look at a partnering agreement which it is anticipated will contain upfront, milestone and royalty payments.

Broker press

  • Page 1 of 4
  • 12/03/14
    +0.25 +11.25

    Daniel Stewart reiterates its "buy" rating and raised its price target to 25.6p from 18.9p.

  • 20/07/11

    Press: 20.07.11: -1.62, (4.38) Press: Plethora Solutions fell on news that full-year results would be lower than expected. Source - Financial Times

  • 03/12/10

    Press: 03.12.10: -0.75, (10.25) Press: Plethora Solutions lost ground following a placing of 8.23m shares at 8.5p. The GBP750,000 raised is to... read more

  • 08/09/10
    +1.50 +13.00

    an article in the Mail reports: Plethora Solutions rose 0.5p to 11.5p. Broker FinnCap, which has a target price of 57p, says the company already has five products in... read more

  • 27/04/10
    +0.00 +14.75

    the U.K. launch of Johnson & Johnson?s (JNJ) premature ejaculation pill Priligy highlights the prospects for Plethora Solutions? (PLE.LN) premature ejaculation spray PSD502, says FinnCap analyst Keith Redpath. Priligy has gone on sale for GBP25 a tablet, and if 33,000 men took one a month sales would hit GBP10 million a year, he says. Notes 33,000 men represent less than 0.2% of the estimated U.K. male population affected by the condition. PSD502 has advantages over Priligy: it has fewer side effects and is effective within seconds, not hours, Redpath says. PSD502 launch is expected in 12 to 18 months. Has 57p target.

Director dealings

  • Page 1 of 5
Date Director Trans Amount Type Price(p) Value (£) Holding %
29/08/14 J. Mellon TAKE 25,299,490 ORD 9.00 2,276,954 145,812,298 23.61
15/10/13 J. Mellon TAKE 20,000,000 ORD 9.00 1,800,000 116,512,808 29.50
15/10/13 J.R. Openshaw TAKE 333,500 ORD 9.00 30,015 750,169 0.20
15/10/13 G. Bailey TAKE 555,600 ORD 9.00 50,004 555,600 0.10
15/10/13 M.G. Wyllie TAKE 333,500 ORD 9.00 30,015 1,353,327 0.30

BASIC RESULTS INFORMATION

  • Page 1 of 4
Date Type Turnover Profit EPS (p) Dividend (p) Currency
30/06/14 Interim 0.00 -1.73 -0.42 0.00 GBX
31/12/13 Full year 0.00 -8.76 -2.60 0.00 GBX
30/06/13 Interim 0.00 -1.06 -0.26 0.00 GBX
31/12/12 Full year 0.58 -3.87 -1.90 0.00 GBX
30/06/12 Interim 0.28 -2.03 -1.00 0.00 GBX
  • Additional Information
    Market
    AIM
    EPIC
    PLE
    Share Price
    6.25p
    Change
    0
    Volume
    720,964
    Dividend
    0
    EPS
    -2.60
    Shares
    632.21 m
    Offer
    6.5
    Bid
    6
    Avg. Vol
    84,012
    Yield
    0.00
    P/E
    0.54
    Mkt Cap
    £39.51 m
  • Contact Information

    REGISTERED OFFICE

    Hampden House 

    Monument Business Park 

    Warpsgrove Lane 

    Chalgrove 

    Oxfordshire 

    OX44 7RW 

    Corporate Information

    Nominated Advisor and Joint Broker

    Daniel Stewart & Company Plc

    36 Old Jewry

    London

    EC2R 8DD

     

    Joint Broker

    Hybridan LLP

    29 Throgmorton Street

    London

    EC2N 2AT

     

    Solicitors to the Company

    Proskauer Rose LLP 

    Ninth Floor

    Ten Bishops Square

    London

    E1 6EG

     

    Bankers

    Lloyds TSB Bank plc

    2nd Floor

    PO Box 18436

    39 Threadneedle Street

    London EC2R 8PT

     

    Registrars

    Equiniti Limited

    Aspect House

    Spencer Road

    Lancing

    West Sussex BN99 6QQ

     

    Independent Auditors

    Pricewaterhouse Coopers

    Chartered Accountants & Statutory Auditors

    Abacus House 

    Castle Park

    Cambridge

    CB3 0AN

  • ProactiveInvestors on Facebook